FLT3 programme licensing opportunity
Sentinel Oncology is pleased to announce that its FLT3 kinase programme is available for partnering.
Mutations in the FLT3 gene are amongst the most frequent genetic defects found in acute myeloid leukemia (AML). Sentinel Oncology has developed a novel lead series of small molecule drugs which act as potent inhibitors of FLT3 and represent an excellent opportunity to develop pre-clinical candidate drugs... read more
For more information about the Sentinel Oncology p70S6 kinase programme, visit our website at www.sentineloncology.com or contact us to arrange a collaborative discussion.
March 30, 2010
Sentinel Oncology will be at the following events this year
18th - 22nd April 2015
AACR - Philadelphia
29th May - 2nd June 2015
ASCO - Chicago
15th - 18th June 2015
BIO - Philadelphia
5th - 9th November 2015
EORTC-NCI-AACR - Boston